Fate Therapeutics Inc. (FATE)
NASDAQ
2.11
+0.02 (+0.96%)
Closed
Oct 23, 2026
Day's Range
2.022.14
52 wk Range
0.95003.23
Financial Statements - FATE - Fate Therapeutics Inc.
Revenue
6.64M▼ 51.2%
Net Income
-136.31M▲ 26.8%Net Margin -2051.1%
EBITDA
-135.04M▲ 17.0%
Free Cash Flow
-112.03M▲ 9.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 6.64M | 13.63M | 63.53M | 96.30M | 55.84M | 31.43M |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -147.70M | -195.53M | -190.51M | -308.38M | -216.99M | -128.08M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 337K | -8.01M | 12.39M | 20.82M | 3.53M | -47.70M |
| Pre Tax Income | -136.31M | -186.26M | -160.92M | -281.72M | -212.15M | -173.38M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -136.31M | -186.26M | -160.92M | -281.72M | -212.15M | -173.38M |
| EPS Basic | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.1 |
| EPS Diluted | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.1 |
| Basic Shares Outstanding | 118.78M | 113.68M | 98.41M | 96.82M | 94.74M | 82.38M |
| Diluted Shares Outstanding | 118.78M | 113.68M | 98.41M | 96.82M | 94.74M | 82.38M |
| Ebit | -147.70M | -195.53M | -190.51M | -308.38M | -216.99M | -128.08M |
| Ebitda | -135.04M | -162.65M | -174.74M | -314.93M | -214.67M | -77.29M |
| Net Income Continuous Operations | -136.31M | -186.26M | -160.92M | -281.72M | -212.15M | -173.38M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
